Background and aim: Myasthenia gravis (MG) is a B lymphocyte–mediated disease affecting neuromuscular transmission. The clinical course of MG is unpredictable due to the fluctuating nature and heterogeneity of the disease. Increased levels of free light chains (FLC), which reflect B cell activation, have been detected in different autoimmune disorders. In this study, we evaluated the potential role of FLC as diagnostic and prognostic biomarkers of MG. Materials and methods: 74 MG patients and 52 healthy individuals were included in the study. Serum FLC levels were measured by turbidimetric assay (Freelite, The Binding Site Group Ltd) on the Optilite Analyser System in both groups. In MG patients, anti-AChR and anti-MuSK autoantibodies were detected by enzyme-linked immunosorbent assay. Results: MG patients displayed significantly higher serum κ and total FLC levels than controls, respectively for κFLC 16.0 vs 13.8 mg/L and for total FLC 29.8 vs 25.9 mg/L. Moreover, increased κFLC levels were observed in seropositive MG patients. No association was observed between serum FLC levels and clinical manifestations of disease as well as with severity, age at MG onset, thymoma and treatment. Conclusion: Increased levels of κFLC and total FLC could serve as biomarkers to support the diagnosis of MG.

Gambino C.M., Agnello L., Lo Sasso B., Giglio R.V., Di Stefano V., Candore G., et al. (2022). The role of serum free light chain as biomarker of Myasthenia Gravis. CLINICA CHIMICA ACTA, 528, 29-33 [10.1016/j.cca.2022.01.004].

The role of serum free light chain as biomarker of Myasthenia Gravis

Gambino C. M.
Primo
;
Agnello L.
Secondo
;
Lo Sasso B.;Giglio R. V.;Di Stefano V.;Candore G.;Pappalardo E. M.;Ciaccio A. M.;Brighina F.;Ciaccio M.
Ultimo
2022-01

Abstract

Background and aim: Myasthenia gravis (MG) is a B lymphocyte–mediated disease affecting neuromuscular transmission. The clinical course of MG is unpredictable due to the fluctuating nature and heterogeneity of the disease. Increased levels of free light chains (FLC), which reflect B cell activation, have been detected in different autoimmune disorders. In this study, we evaluated the potential role of FLC as diagnostic and prognostic biomarkers of MG. Materials and methods: 74 MG patients and 52 healthy individuals were included in the study. Serum FLC levels were measured by turbidimetric assay (Freelite, The Binding Site Group Ltd) on the Optilite Analyser System in both groups. In MG patients, anti-AChR and anti-MuSK autoantibodies were detected by enzyme-linked immunosorbent assay. Results: MG patients displayed significantly higher serum κ and total FLC levels than controls, respectively for κFLC 16.0 vs 13.8 mg/L and for total FLC 29.8 vs 25.9 mg/L. Moreover, increased κFLC levels were observed in seropositive MG patients. No association was observed between serum FLC levels and clinical manifestations of disease as well as with severity, age at MG onset, thymoma and treatment. Conclusion: Increased levels of κFLC and total FLC could serve as biomarkers to support the diagnosis of MG.
https://www.sciencedirect.com/science/article/pii/S0009898122000134?via=ihub
Gambino C.M., Agnello L., Lo Sasso B., Giglio R.V., Di Stefano V., Candore G., et al. (2022). The role of serum free light chain as biomarker of Myasthenia Gravis. CLINICA CHIMICA ACTA, 528, 29-33 [10.1016/j.cca.2022.01.004].
File in questo prodotto:
File Dimensione Formato  
The role of serum free light chain as biomarker of Myasthenia Gravis.pdf

non disponibili

Tipologia: Post-print
Dimensione 470.31 kB
Formato Adobe PDF
470.31 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/535893
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact